Poging GOUD - Vrij

Impact Of Modicare

Healthcare Radius

|

August 2018

If effectively rolled out, the NHPS is likely to transform the Indian healthcare narrative over the next decade

- Kaustav Ganguli

Impact Of Modicare

The National Health Protection Scheme (NHPS), launched by the central Government, is being referred to as the world’s largest health insurance plan. The plan envisages covering 10 crore poor and vulnerable families which amounts to approximately 50 crore beneficiaries. The coverage amount has been set at Rs 5 lakh per family per year for secondary and tertiary care hospitalisation. This amount is significantly higher than the cover provided by other central or state Government schemes. Over a period, the scheme is expected to subsume the existing central scheme, Rashtriya Swasthya Bima Yojana (RSBY), as well as many state insurance schemes.

The implications of NHPS for the Indian healthcare sector must be understood in terms of its potential impact on patients, providers and payors, which in this case is the Government.

Let us first understand the outlook related to patients. The NHPS is likely to spawn greater patient demand for healthcare services. This demand will be driven by increased population coverage, enhanced cover amount per family and procedural ease. The RSBY, the predecessor of NHPS, is estimated to have been rolled out to approximately 36 million families over a 10-year time-period against a targeted coverage of 60 million families.

The NHPS, on the other hand, is targeting coverage for 100 million families. In a conservative scenario, if the NHPS achieves ~60% of this declared target over the next 5-6 years, even then an incremental ~24 million families are likely to be covered under this scheme. That translates into an additional 105-110 million lives getting covered. The NHPS is also expected to address the lopsided demand-supply gap across specific geographies like the Northern and Southern states in India as well as the gap between metros and non-metros.

MEER VERHALEN VAN Healthcare Radius

Healthcare Radius

Healthcare Radius

VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM

Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.

time to read

1 mins

December 2025

Healthcare Radius

Healthcare Radius

A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026

The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.

time to read

12 mins

December 2025

Healthcare Radius

Healthcare Radius

FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA

From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.

time to read

6 mins

December 2025

Healthcare Radius

ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US

Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS

Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL

Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH

Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS

By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”

time to read

7 mins

December 2025

Healthcare Radius

Healthcare Radius

MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM

Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.

time to read

1 min

December 2025

Translate

Share

-
+

Change font size